Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter (mcL)
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 2,500/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 2,500/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Leukocytes >= 3,000/microliter
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients residing in prison
Patients must be either:
Patients must:
Patients must =< 25
ALL PATIENTS
Patients with prolactinomas
Patients with T4 disease
Patients with N3 disease
Patients must either:
Patients must have:
Patients who are in-patients.
Splenectomized patients
Patients must have either:
Patients with MEN 2b (since these patients may have megacolon)
Patients who either
ALL PATIENTS:
Patients may be:
Patients must have:
Patients who have:
Patients who:
Patients with:
Patients must have:
Patients must have:
For all patients:
ALL PATIENTS:
Patients with:
All patients must:
Patients who either
Patients with galactosemia
PATIENTS
Patients who are delirious
PATIENTS: Find conversations around religion or spirituality emotionally upsetting
PATIENTS:
PATIENTS
PATIENTS WITH BRONJ:
PATIENTS WITHOUT BRONJ:
Patients
PATIENTS:
Active breast-feeding is also not allowed on study enrollment
Interest in future fertility
Interest in future fertility
interest in future fertility;
Are interested in future fertility,
Interest in future fertility
Women desiring future fertility except in the screening arm of the trial
Unmanageable claustrophobia
ECOG < 2
ECOG of 0-1 at screen
ECOG ? 2
ECOG ? 1
Patient with ECOG ? 2
ECOG 0-2
ECOG 0 or 1
ECOG 0 or 1
ECOG 0-2
PART II: ECOG 0-1
ECOG 3 - 4
ECOG 0 or 1
ECOG 0 or 1
ECOG of 0 or 1
ECOG 0-2
ECOG ?2.
Patient with ECOG ? 2
ECOG 0,1
ECOG 3 or 4
ECOG ? 1
ECOG of 0 to 1
ECOG ?2.
ECOG 0 or 1
ECOG ? 2
ECOG 0 or 1
ECOG 0 to 2
ECOG=2 or better
ECOG of 0 or 1
ECOG of 0 or 1.
ECOG ? 2.
ECOG 0-1
ECOG 0 or 1
ECOG ? 2
ECOG 0, 1 or 2
ECOG of 0 or 1
ECOG > 2
ECOG 0 or 1 at enrolment.
ECOG 0, 1, or 2
Inability or unwillingness to swallow pills
Inability or unwillingness to swallow pills
Inability or unwillingness to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability or unwillingness to swallow whole pills
Inability to swallow pills;
Inability to swallow pills
Inability to swallow pills
Inability or unwillingness to swallow pills
Inability or unwillingness to swallow pills.
Inability or unwillingness to swallow pills.
Inability or unwillingness to swallow pills
Inability to swallow pills
Inability or unwillingness to swallow pills
Inability or unwillingness to swallow pills
Inability to swallow pills
Inability or unwillingness to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability to swallow pills
Inability or unwillingness to swallow pills
History of sarcoidosis syndrome
History of sarcoidosis syndrome
History of sarcoidosis
History of sarcoidosis syndrome
History of sarcoidosis syndrome
History of sarcoidosis syndrome
History of sarcoidosis syndrome
History of sarcoidosis syndrome.
History of sarcoidosis syndrome
History of sarcoidosis
History of sarcoidosis syndrome
Bladder post-void residual volume (PVR) of >750 mL.
Bladder post-void residual volume of >500 mL.
Post Void Residual (PVR) bladder volume > 250 mL
Bladder Post-Void Residual Volume (PVR) of > 250-mL.
Concomitant illness associated with a likely survival of < 1 year
Concomitant illness associated with a likely survival of < 1 year
Concomitant illness associated with a likely survival of < 1 year
Concomitant illness associated with a likely survival of < 1 year
Concomitant illness associated with a likely survival of < 1 year
Concomitant illness associated with a likely survival of < 1 year
Concomitant illness associated with a likely survival of < 1 year
